These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34941096)

  • 1. Hepatotoxicity associated with the use of teriflunomide in a patient with multiple sclerosis: A case report.
    Ferreira CM; Vasconcelos-Pereira EF; Oliveira VM; Salgado PR; Domingos JA; Monreal MTFD; Guerra-Shinohara EM; Gubert VT
    Medicine (Baltimore); 2021 Dec; 100(51):e28246. PubMed ID: 34941096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells.
    Tilly G; Cadoux M; Garcia A; Morille J; Wiertlewski S; Pecqueur C; Brouard S; Laplaud D; Degauque N
    Front Immunol; 2021; 12():730342. PubMed ID: 34721394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teriflunomide-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome.
    Khurana D; Kaur G; Sendhil Kumaran M; Choudhary R; Ashraf R; Thakur V
    Clin Exp Dermatol; 2021 Jan; 46(1):166-169. PubMed ID: 32557734
    [No Abstract]   [Full Text] [Related]  

  • 4. Pulmonary embolism in patients with multiple sclerosis treated with teriflunomide: A series of three cases.
    Krajnc N; Brecl Jakob G; Gomezelj S; Šega Jazbec S
    Clin Neurol Neurosurg; 2021 Jul; 206():106685. PubMed ID: 34020325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teriflunomide, a potential novel cause of chronic active colitis.
    Kővári B; Zachs J; Murchie B; Lauwers GY
    Histopathology; 2020 Dec; 77(6):1000-1001. PubMed ID: 32323888
    [No Abstract]   [Full Text] [Related]  

  • 6. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An updated review of teriflunomide's use in multiple sclerosis.
    Miller AE
    Neurodegener Dis Manag; 2021 Oct; 11(5):387-409. PubMed ID: 34486382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.
    Papp V; Buron MD; Siersma V; Rasmussen PV; Illes Z; Kant M; Hilt C; Mezei Z; Roshanisefat H; Sejbæk T; Weglewski A; van Wingerden J; Geertsen SS; Bramow S; Sellebjerg F; Magyari M
    PLoS One; 2021; 16(5):e0250820. PubMed ID: 34003862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teriflunomide-associated urolithiasis: a new adverse reaction explained by its uricosuric effect.
    Largeau B; Béra F; Vannier J; Jonville-Béra AP
    Fundam Clin Pharmacol; 2021 Oct; 35(5):930-932. PubMed ID: 33458875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Teriflunomide in Chinese Patients with Relapsing Forms of Multiple Sclerosis: A Subgroup Analysis of the Phase 3 TOWER Study.
    Qiu W; Huang DH; Hou SF; Zhang MN; Jin T; Dong HQ; Peng H; Zhang CD; Zhao G; Huang YN; Zhou D; Wu WP; Wang BJ; Li JM; Zhang XH; Cheng Y; Li HF; Li L; Lu CZ; Zhang X; Bu BT; Dong WL; Fan DS; Hu XQ; Xu XH;
    Chin Med J (Engl); 2018 Dec; 131(23):2776-2784. PubMed ID: 30511679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients.
    Gil-Bernal R; González-Caballero JL; Espinosa-Rosso R; Gómez-Gómez C
    Sci Rep; 2021 Jun; 11(1):12533. PubMed ID: 34131191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Miller AE; Wolinsky JS; Kappos L; Comi G; Freedman MS; Olsson TP; Bauer D; Benamor M; Truffinet P; O'Connor PW;
    Lancet Neurol; 2014 Oct; 13(10):977-86. PubMed ID: 25192851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ▼Teriflunomide for multiple sclerosis.
    Drug Ther Bull; 2014 Jul; 52(7):81-4. PubMed ID: 25012149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
    Montalban X; Vermersch P; Arnold DL; Bar-Or A; Cree BAC; Cross AH; Kubala Havrdova E; Kappos L; Stuve O; Wiendl H; Wolinsky JS; Dahlke F; Le Bolay C; Shen Loo L; Gopalakrishnan S; Hyvert Y; Javor A; Guehring H; Tenenbaum N; Tomic D;
    Lancet Neurol; 2024 Nov; 23(11):1119-1132. PubMed ID: 39307151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Ponesimod Compared with Teriflunomide in Female Patients with Relapsing Multiple Sclerosis: Findings from the Pivotal OPTIMUM Study.
    Jones RR; Turkoz I; Ait-Tihyaty M; DiBernardo A; Houtchens MK; Havrdová EK
    J Womens Health (Larchmt); 2024 Apr; 33(4):480-490. PubMed ID: 38301149
    [No Abstract]   [Full Text] [Related]  

  • 17. Teeth loss after teriflunomide treatment: Casual or causal? A short case series.
    Vacchiano V; Frattaruolo N; Mancinelli L; Foschi M; Carotenuto A; Scandellari C; Piattelli M; Brescia Morra V; Lugaresi A
    Mult Scler Relat Disord; 2018 Aug; 24():120-122. PubMed ID: 29982109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience.
    Vukusic S; Coyle PK; Jurgensen S; Truffinet P; Benamor M; Afsar S; Purvis A; Poole EM; Chambers C
    Mult Scler; 2020 Jun; 26(7):829-836. PubMed ID: 30968734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teriflunomide for the treatment of relapsing-remitting multiple sclerosis.
    Miller AE
    Expert Rev Clin Immunol; 2015 Feb; 11(2):181-94. PubMed ID: 25511008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphocytic colitis in the setting of teriflunomide use for relapsing multiple sclerosis.
    Son M; McEwan L; Ubaidat M; Bovell K; Morrow SA
    Mult Scler; 2020 Nov; 26(13):1801-1803. PubMed ID: 32031458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.